On April 26, Hailir Group announced a number of new investments to be launched in Shandong Hailir Chemical Co., Ltd, a wholly owned subsidiary of the Group. The new investments include 3,000-ton prothioconazole technical and other technicals with associated by-products, aiming to meet the long-term requirements of capacity expansion and business growth of the company.
The project is located in Binhai Economic and Technological Development Zone, with a total investment of Yuan300 million, scheduled for completion within 18 months. Upon completion, the project will annually generate 3,000-ton prothioconazole technical and some other technicals with associated by-products.
Prothioconazole is a novel broad-spectrum triazolthion fungicide for control of a large variety of food crop diseases on wheat, barley, rapeseed, peanut, rice and legumes. It is remarkably effective for control of all wheat diseases, such as wheat and barley powdery mildew, banded sclerotial blight, wilt, leaf spot, rust, sclerotinia sclerotiorum, net blotch and rhynchosporium secalis. It is also effective for prevention and control of soil-borne diseases of rapeseed and peanut. The results of large number of field efficacy tests show that prothioconazole is not only highly safe to crops, effective against diseases, but can also increase yield significantly. Compared with triazole fungicides, prothioconazole has a broader bactericidal spectrum. In light of its satisfactory fungicidal effect, there is a great future market prospect.
According to Hailir’s announcement, the company’s investments, as mentioned above, are effective approaches to the company’s sustainable development. After completion of the project, taking into account the existing capacity of 2,000 tons of prothioconazole in Shandong Hailir Chemical Co., Ltd, the production capacity of prothioconazole in Shandong Hailir will reach 5,000 tons. Coupled with the phase II project of Qingdao Hengning Biotechnology Co., Ltd with a designed capacity of 8,000 tons of prothioconazole, the company’s total production capacity of prothioconazole will reach 13,000 tons in the future. Propionimetrazole will become one of the company’s dominant products, which will pave the way for the company’s sound development on a long-term basis to contribute to its continued business growth and increase of competitive competency.